Ruby 3 mg/0,03 mg FC tablets
PDF Leaflet Revision Date: 18 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of pregnancy (oral contraception).
Dosage (summary)
One tablet daily for 28 days, starting on day 1 of the menstrual cycle.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Antibiotics
- Enzyme inducers
- Potassium-sparing medications
Contraindications
- Hypersensitivity to components
- Thrombosis history
- Severe hepatic disease
- Severe renal insufficiency
- Breast cancer history
Common side effects
- Nausea
- Headache
- Depression
- VTE
- Migraine
Counselling Points
- Use additional contraception for first 7 days if starting RUBY
- Report any unusual symptoms immediately
- Regular breast examinations recommended
Serious warnings
- Increased risk of thromboembolism
- Monitor for signs of thrombosis
- Potential liver tumors
Important Disclaimer
The Ruby 3 mg/0,03 mg FC tablets professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
